Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Iloprost for Lung Cancer Chemoprevention
NCT05411107Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in lung cancer comparing Iloprost with Placebo (2 arms). Primary endpoint: Change in numerical grade of the worst dysplastic lesion per subject on bronchoscopy at 6 months. Planned start Jun 2024; status: withdrawn.
02
Drugs
iloprost
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT05411107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411107.